{
    "nctId": "NCT06316531",
    "briefTitle": "A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer",
    "officialTitle": "A Randomized Controlled Phase III Clinical Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 268,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. No gender limit;\n3. Age \u226518 years old and \u226475 years old at the time of signing the informed consent;\n4. expected survival time \u22653 months;\n5. Patients with histologically or cytologically confirmed, unresectable, locally advanced or metastatic HER2-positive breast cancer;\n6. Provide the latest tumor tissues to the central laboratory for HER2 and HR detection;\n7. Must have at least one measurable target lesion that meets the RECIST v1.1 definition;\n8. ECOG 0 or 1;\n9. Toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 defined by NCI-CTCAE v5.0;\n10. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n11. Blood transfusion is not allowed within 14 days before the first use of the study drug, and no cell growth factor is allowed;\n12. Coagulation function: international normalized ratio (INR) \u22641.5 and activated partial thromboplastin time (APTT)\u22641.5\u00d7ULN;\n13. Urine protein \u22642+ or \\< 1000mg/24h;\n14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 7 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Received chemotherapy with mitomycin C and nitrosourea within 6 weeks before the first dose, received surgery, chemotherapy, immunotherapy, etc. Within 4 weeks before the first dose, received endocrine therapy, palliative radiotherapy, and anti-tumor therapy approved by NMPA within 2 weeks before the first dose;\n2. Previous use of HER2-ADC in the metastatic background;\n3. Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin;\n4. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;\n5. Complicated with pulmonary diseases leading to severe impairment of lung function;\n6. History of ILD/interstitial pneumonia, current ILD/interstitial pneumonia, or suspected ILD/interstitial pneumonia; According to CTCAE v5.0 was defined as \u2265 grade 3 pulmonary disease and \u2265 grade 2 radiation pneumonitis;\n7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n8. Other primary malignancies diagnosed within 5 years before the first dose;\n9. Poorly controlled hypertension (systolic blood pressure \\&gt; 150 mmHg or diastolic blood pressure \\&gt; 100 mmHg);\n10. Patients with active central nervous system metastases;\n11. Patients with a history of allergy to recombinant humanized antibody or to any of the excipents of BL-M07D1;\n12. Patients with known hypersensitivity or delayed hypersensitivity to certain components of T-DM1 or similar drugs, or known contraindications to T-DM1;\n13. History of autologous or allogeneic stem cell transplantation or organ transplantation;\n14. Anthracycline-equivalent cumulative dose of adriamycin \\> 360 mg/m2;\n15. Human immunodeficiency virus antibody positive, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection;\n16. Serious infection within 4 weeks before the first dose of study drug; There was active pulmonary inflammation at the time of screening;\n17. Patients with massive or symptomatic effusions or poorly controlled effusions;\n18. Receiving active antiinflammatory drugs or any form of immunosuppressive therapy before randomization;\n19. A history of severe neurological or psychiatric illness;\n20. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n21. Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea;\n22. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;\n23. Patients who were deemed by the investigator to be ineligible for the study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}